Value of HBsAg quantification in individualized anti-HBV treatment with nucleos(t)ide analogues
10.3969/j.issn.1001-5256.2019.08.038
- VernacularTitle:HBsAg定量在核苷(酸)类似物个体化抗HBV治疗中的应用价值
- Author:
Youqian ZHOU
1
;
Cui LI
Author Information
1. Department of Infectious Diseases, 922 Hospital of PLA & Xiangnan Hospital Affiliated to Hunan Normal University, Hengyang, Hunan 421002, China
- Publication Type:Research Article
- Keywords:
hepatitis B virus;
hepatitis B surface antigens;
nucleosides;
nucleotides;
therapeutics
- From:
Journal of Clinical Hepatology
2019;35(8):1821-1823
- CountryChina
- Language:Chinese
-
Abstract:
Nucleos(t)ide analogues can effectively prevent or delay disease progression in patients with chronic hepatitis B virus (HBV) infection, but the course of treatment is long and long-term medication may bring the risk of adverse drug reactions and drug resistance. Recent studies have found that HBsAg quantification has an important value in individualized antiviral treatment for patients with chronic hepatitis B. This article reviews the research advances in the value of HBsAg quantification in judgment of indication for antiviral treatment with nucleos(t)ide analogues, prediction of therapeutic outcome, and timing of drug withdrawal, and it is pointed out that HBsAg quantification can help to determine the timing of antiviral treatment and predict the treatment outcome of patients at the beginning of antiviral treatment, during the treatment process, and when drug withdrawal is considered. Further studies are needed to determine the optimal predictive thresholds for different stages of HBeAg-positive or HBeAg-negative patients, as well as the optimal time point and thresholds for predicting treatment outcome during antiviral treatment with different nucleos(t)ide analogues.
